Healthcare / BiotechnologyNYSE American
$0.80
-0.10 (-11.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.4M · quality 82.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
142.7%
↑Gross Margin
-45.5%
↓Debt/Equity
-0.50
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
-1.4%
FCF CAGR
—
FCF margin
-12880.7%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $88000.0 · net income $-14.0M · FCF $-11.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $88000.00 | $88000.00 | $170000.00 | $202000.00 | $141000.00 | $135000.00 | $163000.00 | $140000.00 | $367000.00 | $437000.00 | $92000.00 | $133000.00 | $197000.00 | $150000.00 | $213000.00 | $161000.00 | $135000.00 | $111000.00 |
| Net Income | $-14.0M | $-14.0M | $-17.3M | $-29.0M | $-19.4M | $-19.1M | $-14.4M | $-9.4M | $-9.8M | $-8.3M | $-7.5M | $-15.2M | $-17.4M | $-16.2M | $-17.4M | $-9.0M | $-13.1M | $-7.2M |
| EBITDA | $-12.9M | $-12.9M | $-16.5M | $-28.7M | $-19.7M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -8.62 | -8.62 | -30.92 | -59.94 | -39.96 | -38.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | -45.5% | -45.5% | 81.8% | 79.2% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -13254.5% | -13254.5% | -11630.6% | -15800.0% | -14129.8% | -13954.1% | -9295.7% | -8887.9% | -3132.4% | -2612.4% | -15004.3% | -12518.8% | -9694.9% | -11444.7% | -9549.3% | -8878.9% | -12138.5% | -11949.5% |
| Net Margin | -15861.4% | -15861.4% | -10188.2% | -14337.6% | -13790.8% | -14168.1% | -8834.4% | -6717.1% | -2677.7% | -1889.9% | -8154.3% | -11451.1% | -8857.9% | -10816.7% | -8147.4% | -5599.4% | -9730.4% | -6468.5% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | -0.50 | -0.50 | -2.22 | 0.07 | 0.02 | — | 0.03 | 0.16 | 0.42 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.53 | 0.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-11.3M | $-11.3M | $-15.4M | $-21.9M | $-16.4M | $-14.0M | $-10.4M | $-9.1M | $-10.7M | $-8.0M | $-7.5M | $-16.3M | $-14.5M | $-17.7M | $-18.9M | $-11.9M | $-12.6M | $-9.6M |
| Returns | ||||||||||||||||||
| ROE | 142.7% | 142.7% | 1310.1% | -283.0% | -50.5% | -33.6% | -23.5% | -70.0% | -176.1% | -94.9% | -48.4% | -74.8% | -69.8% | -55.4% | -38.8% | — | — | — |
| Valuation | ||||||||||||||||||
| P/B | — | — | — | 2.03 | 0.58 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -48.2% | -48.2% | -15.8% | 43.3% | — | -17.2% | 16.4% | -61.9% | -16.0% | 375.0% | -30.8% | -32.5% | 31.3% | -29.6% | 32.3% | 19.3% | 21.6% | — |
| EPS Growth | 72.1% | 72.1% | 48.4% | -50.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-88.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-30.92 → -8.62
Residual
-88.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.